CVRx Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

CVRx hat ein Gesamteigenkapital von $66.3M und eine Gesamtverschuldung von $29.3M, was einen Verschuldungsgrad von 44.2% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $106.2M bzw. $39.9M.

Wichtige Informationen

53.1%

Verhältnis von Schulden zu Eigenkapital

US$29.32m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$70.40m
Eigenkapital	US$55.25m
Gesamtverbindlichkeiten	US$40.73m
Gesamtvermögen	US$95.98m

Jüngste Berichte zur Finanzlage

Recent updates

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Jul 31

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

Jun 18

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%

May 04

Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt

Apr 10

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%

Feb 29

Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%

Nov 11

Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

Aug 20

CVRx Pursues Revenue Growth But Operating Losses Worsen

Aug 05

CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales

Jun 21

We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth

Apr 12

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Feb 18

CVRx: The Path To 7x Investment Returns

Jan 07

CVRx: High Risk And High Potential Reward

Jul 04

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CVRXDie kurzfristigen Aktiva des Unternehmens ($92.0M) übersteigen seine kurzfristigen Passiva ($9.1M).

Langfristige Verbindlichkeiten: CVRXDie kurzfristigen Vermögenswerte des Unternehmens ($92.0M) übersteigen seine langfristigen Verbindlichkeiten ($31.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CVRX über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob das Verhältnis von Schulden zu Eigenkapital in den letzten 5 Jahren gesunken ist ( CVRX).

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: CVRX auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: CVRX über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 26.2% pro Jahr zurückgeht

CVRx Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt

Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth

Recent updates

CVRx, Inc. Announces Board Changes

President recently bought US$251k worth of stock

CVRx, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Second quarter 2024 earnings: EPS misses analyst expectations

CVRx, Inc. to Report Q2, 2024 Results on Jul 29, 2024

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell Small Cap Comp Value Index

CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

New major risk - Share price stability

CVRx, Inc. Announces Executive Appointments

Consensus EPS estimates fall by 28%

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%

CVRx, Inc. Provides Earnings Guidance for Second Quarter and Full Year of 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CVRx, Inc., Annual General Meeting, Jun 04, 2024

CVRx, Inc. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%

Chief Marketing & Strategy Officer notifies of intention to sell stock

CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12

Full year 2023 earnings: EPS exceeds analyst expectations

CVRx, Inc. to Report Q4, 2023 Results on Jan 25, 2024

CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer

CVRx, Inc. Announces Nadim Yare Retires as President

CVRx, Inc. Receives FDA Approval for Expanded Labing of Barostim

Price target increased by 16% to US$23.60

Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%

New minor risk - Share price stability

CVRx, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Price target decreased by 9.3% to US$19.40

CVRx, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. Revises Financial Guidance for the Full Year 2023

CVRx, Inc. to Report Q2, 2023 Results on Jul 25, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. to Report Q4, 2022 Results on Jan 26, 2023

CVRx, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 and Provides Revenue Guidance for the First Quarter and Full Year of 2023

CVRx, Inc. Appoints Kevin Hykes to Board of Directors

Price target increased to US$17.25

Chief Marketing & Strategy Officer notifies of intention to sell stock

Price target increased to US$14.75

CVRx, Inc. Launches New Barostim NEO2(TM) Implantable Pulse Generator

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. announced that it expects to receive $65 million in funding from Innovatus Capital Partners, LLC

CVRx, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

CVRx Pursues Revenue Growth But Operating Losses Worsen

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CVRx, Inc. Revises Earnings Guidance for the Full Year of 2022

CVRx, Inc. to Report Q2, 2022 Results on Jul 28, 2022

CVRx, Inc. Launches A New Barostim Programmer

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell 2500 Value Index

CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales

CVRx, Inc. Receives U.S. Food and Drug Administration Approval for Magnetic Resonance Conditional Labeling for Its Barostim System

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

CVRx, Inc., Annual General Meeting, Jun 07, 2022

CVRx, Inc. to Report Q1, 2022 Results on Apr 25, 2022

We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth

Consensus forecasts updated

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Full year 2021 earnings: EPS exceeds analyst expectations

CVRx, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

CVRx, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Cvrx, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2021 and First Quarter and Full Year of 2022

CVRx: The Path To 7x Investment Returns